Introduction:Basic information about CAS 6506-37-2|Nimorazole, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Nimorazole |
|---|
| CAS Number | 6506-37-2 | Molecular Weight | 226.232 |
|---|
| Density | 1.4±0.1 g/cm3 | Boiling Point | 443.0±35.0 °C at 760 mmHg |
|---|
| Molecular Formula | C9H14N4O3 | Melting Point | / |
|---|
| MSDS | / | Flash Point | 221.7±25.9 °C |
|---|
Names
| Name | 4-[2-(5-nitroimidazol-1-yl)ethyl]morpholine |
|---|
| Synonym | More Synonyms |
|---|
Nimorazole BiologicalActivity
| Description | Nimorazole (K-1900) is a nitroimidazole anti-infective. |
|---|
| Related Catalog | Signaling Pathways >>Anti-infection >>ParasiteResearch Areas >>Infection |
|---|
| Target | Antiparasitic |
|---|
| In Vitro | Nimorazole significantly improves the effect of radiotherapeutic management of supraglottic and pharynx tumors and can be given without major side-effects [1, 2]. Nimorazole is the only such agent to have shown a significant effect in a randomized controlled trial in head and neck cancer [3]. |
|---|
| References | [1]. Overgaard, J., et al., A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol, 1998. 46(2): p. 135-46. [2]. Roy, R.B., S.M. Laird, and L. Heasman, Treatment of trichomoniasis in the female. A comparison of metronidazole and nimorazole. Br J Vener Dis, 1975. 51(4): p. 281-4. [3]. Henk, J.M., K. Bishop, and S.F. Shepherd, Treatment of head and neck cancer with CHART and nimorazole: phase II study. Radiother Oncol, 2003. 66(1): p. 65-70. |
|---|
Chemical & Physical Properties
| Density | 1.4±0.1 g/cm3 |
|---|
| Boiling Point | 443.0±35.0 °C at 760 mmHg |
|---|
| Molecular Formula | C9H14N4O3 |
|---|
| Molecular Weight | 226.232 |
|---|
| Flash Point | 221.7±25.9 °C |
|---|
| Exact Mass | 226.106583 |
|---|
| PSA | 76.11000 |
|---|
| LogP | -0.08 |
|---|
| Appearance of Characters | light yellow solid |
|---|
| Vapour Pressure | 0.0±1.1 mmHg at 25°C |
|---|
| Index of Refraction | 1.637 |
|---|
| InChIKey | MDJFHRLTPRPZLY-UHFFFAOYSA-N |
|---|
| SMILES | O=[N+]([O-])c1cncn1CCN1CCOCC1 |
|---|
| Storage condition | -20℃ |
|---|
Toxicological Information
CHEMICAL IDENTIFICATION - RTECS NUMBER :
- QE7400000
- CHEMICAL NAME :
- Morpholine, 4-(2-(5-nitroimidazol-1-yl)ethyl)-
- CAS REGISTRY NUMBER :
- 6506-37-2
- LAST UPDATED :
- 199612
- DATA ITEMS CITED :
- 20
- MOLECULAR FORMULA :
- C9-H14-N4-O3
- MOLECULAR WEIGHT :
- 226.27
- WISWESSER LINE NOTATION :
- T6N DOTJ A2- AT5N CNJ ENW
HEALTH HAZARD DATAACUTE TOXICITY DATA - TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 1540 mg/kg
- TOXIC EFFECTS :
- Behavioral - convulsions or effect on seizure threshold
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 1200 mg/kg
- TOXIC EFFECTS :
- Sense Organs and Special Senses (Eye) - lacrimation Behavioral - somnolence (general depressed activity) Behavioral - convulsions or effect on seizure threshold
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Subcutaneous
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 1090 mg/kg
- TOXIC EFFECTS :
- Behavioral - excitement
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 1530 mg/kg
- TOXIC EFFECTS :
- Behavioral - somnolence (general depressed activity) Behavioral - tremor Behavioral - ataxia
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 1200 mg/kg
- TOXIC EFFECTS :
- Sense Organs and Special Senses (Eye) - ptosis Lungs, Thorax, or Respiration - respiratory stimulation
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Subcutaneous
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 1140 mg/kg
- TOXIC EFFECTS :
- Sense Organs and Special Senses (Eye) - ptosis Behavioral - somnolence (general depressed activity) Behavioral - convulsions or effect on seizure threshold
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 14 gm/kg/5W-I
- TOXIC EFFECTS :
- Nutritional and Gross Metabolic - weight loss or decreased weight gain Related to Chronic Data - death Related to Chronic Data - changes in testicular weight
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 72800 mg/kg/26W-I
- TOXIC EFFECTS :
- Nutritional and Gross Metabolic - weight loss or decreased weight gain Related to Chronic Data - death Related to Chronic Data - changes in testicular weight
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 9275 mg/kg/5W-I
- TOXIC EFFECTS :
- Nutritional and Gross Metabolic - weight loss or decreased weight gain Related to Chronic Data - changes in testicular weight
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 2800 mg/kg
- SEX/DURATION :
- female 8-14 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Newborn - live birth index (measured after birth)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 700 mg/kg
- SEX/DURATION :
- female 8-14 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Newborn - live birth index (measured after birth)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 700 mg/kg
- SEX/DURATION :
- female 7-13 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Effects on Newborn - live birth index (measured after birth)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 4200 mg/kg
- SEX/DURATION :
- female 7-13 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 2800 mg/kg
- SEX/DURATION :
- female 7-13 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Effects on Newborn - live birth index (measured after birth)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 700 mg/kg
- SEX/DURATION :
- female 7-13 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)
MUTATION DATA - TYPE OF TEST :
- Mutation in microorganisms
- TEST SYSTEM :
- Microorganism - not otherwise specified
- DOSE/DURATION :
- 250 umol/L
- REFERENCE :
- MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964- Volume(issue)/page/year: 26,483,1974
|
Safety Information
Customs
| HS Code | 2934999090 |
|---|
| Summary | 2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
|---|
Synonyms
| Morpholine, 4-[2- (5-nitroimidazol-1-yl)ethyl]- |
| Nulogyl |
| 4-[2-(5-Nitroimidazol-1-yl)ethyl]morpholine |
| 1-(β-Morpholinoethyl)-5-nitroimidazole |
| Nimorazole |
| Morpholine, 4-[2-(5-nitro-1H-imidazol-1-yl)ethyl]- |
| Morpholine, 4-[2- (5-nitro-1H-imidazol-1-yl)ethyl]- |
| Acterol |
| Acterol forte |
| Esclama |
| Nimorazol |
| 4-[2-(5-Nitro-1H-imidazol-1-yl)ethyl]morpholine |
| Naxogin |
| Morpholine, 4-(2-(5-nitro-1H-imidazol-1-yl)ethyl)- |
| Nimorazolo |
| UNII-469ULX0H4G |
| Nitrimidazine |
| Naxofem |